BASF and Catalent to Collaborate
News Apr 06, 2012
Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.
The companies aim to combine their world-leading expertise to provide pharmaceutical customers with a unique range of seamless solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds.
From feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply, BASF and Catalent provide a full solution to one of the most important pipeline challenges in the industry - getting better treatments to market faster.
BASF has extensive ingredient formulation and material science expertise, as well as world-class excipient products and has been a leader in developing hot melt extrusion technology solutions.
Catalent is the #1 global partner in drug formulation and development as well as in finished oral dose manufacturing, with more than 75 years of experience in providing bioavailability solutions.
Ian Muir, President of Catalent’s Modified Release Technologies business unit, stated, “We are very pleased to collaborate with BASF to bring this unique and impactful solution to our customers. BASF brings significant strengths and expertise that match very well with Catalent’s expertise in offering multiple solutions for poorly soluble compounds; including our Softgel platform and OptiMelt™ hot melt extrusion technologies. Our proven track record of developing, scaling up and manufacturing pharmaceutical products globally also provides for an important seamless integration from development to commercialization and ongoing supply.”
"We are glad to bring our in depth knowledge of polymeric excipients, including innovations like SOLUPLUS® into this open alliance", says Ralf Fink, VP Global Marketing at BASF Pharma Ingredients & Services business unit.
Fink continued, "With our broadest portfolio of solubilizers and excipients for hot-melt extrusion, coupled with Catalent’s strengths in development, formulation and manufacturing, we are in a unique position to solve the solubility challenge. With this open alliance, we help our customers in the development and commercialization of drugs with poor bioavailability."
Catalent has made significant investments in OptiMelt™ hot melt extrusion and fluid bed lab, pilot, and commercial scale equipment at its Schorndorf, Germany facility, OptiMelt™ hot melt extrusion at its Somerset, NJ facility, training and seamless method development to operationalize this open alliance.
BASF is continuously investing in new excipients to provide advanced solutions for the pharmaceutical industry.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018